Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Predicting Cognitive Improvement in Normal Pressure Hydrocephalus Patients Using Preoperative Neuropsychological Testing and Cerebrospinal Fluid Biomarkers.

McGovern RA, Nelp TB, Kelly KM, Chan AK, Mazzoni P, Sheth SA, Honig LS, Teich AF, McKhann GM.

Neurosurgery. 2019 Oct 1;85(4):E662-E669. doi: 10.1093/neuros/nyz102.

PMID:
30937451
2.

Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.

Tariciotti L, Casadei M, Honig LS, Teich AF, McKhann Ii GM, Tosto G, Mayeux R.

J Alzheimers Dis. 2018;65(4):1417-1425. doi: 10.3233/JAD-180548.

3.

Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function.

Xu Z, Lo WS, Beck DB, Schuch LA, Oláhová M, Kopajtich R, Chong YE, Alston CL, Seidl E, Zhai L, Lau CF, Timchak D, LeDuc CA, Borczuk AC, Teich AF, Juusola J, Sofeso C, Müller C, Pierre G, Hilliard T, Turnpenny PD, Wagner M, Kappler M, Brasch F, Bouffard JP, Nangle LA, Yang XL, Zhang M, Taylor RW, Prokisch H, Griese M, Chung WK, Schimmel P.

Am J Hum Genet. 2018 Jul 5;103(1):100-114. doi: 10.1016/j.ajhg.2018.06.006.

4.

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse.

Teich AF, Sharma E, Barnwell E, Zhang H, Staniszewski A, Utsuki T, Padmaraju V, Mazell C, Tzekou A, Sambamurti K, Arancio O, Maccecchini ML.

Alzheimers Dement (N Y). 2018 Jan 18;4:37-45. doi: 10.1016/j.trci.2017.12.001. eCollection 2018.

5.

ZCCHC17 is a master regulator of synaptic gene expression in Alzheimer's disease.

Tomljanovic Z, Patel M, Shin W, Califano A, Teich AF.

Bioinformatics. 2018 Feb 1;34(3):367-371. doi: 10.1093/bioinformatics/btx608.

6.

Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like pathologies and cognitive deficits.

Lacampagne A, Liu X, Reiken S, Bussiere R, Meli AC, Lauritzen I, Teich AF, Zalk R, Saint N, Arancio O, Bauer C, Duprat F, Briggs CA, Chakroborty S, Stutzmann GE, Shelanski ML, Checler F, Chami M, Marks AR.

Acta Neuropathol. 2017 Nov;134(5):749-767. doi: 10.1007/s00401-017-1733-7. Epub 2017 Jun 19.

7.

11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.

Kreisl WC, Lawrence R, Page E, Teich AF, Subramaniam DS, Innis RB, Turner RS.

Neurology. 2017 Mar 7;88(10):1001-1004. doi: 10.1212/WNL.0000000000003693. Epub 2017 Feb 8. No abstract available.

8.

Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer's disease.

Koppensteiner P, Trinchese F, Fà M, Puzzo D, Gulisano W, Yan S, Poussin A, Liu S, Orozco I, Dale E, Teich AF, Palmeri A, Ninan I, Boehm S, Arancio O.

Sci Rep. 2016 Sep 1;6:32553. doi: 10.1038/srep32553.

9.

Erratum to: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Luo J, Lee SH, VandeVrede L, Qin Z, Aissa MB, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR.

Mol Neurodegener. 2016 May 18;11(1):40. No abstract available.

10.

A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR.

Mol Neurodegener. 2016 Apr 29;11:35. doi: 10.1186/s13024-016-0103-6. Erratum in: Mol Neurodegener. 2016;11(1):40.

11.

PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.

Teich AF, Sakurai M, Patel M, Holman C, Saeed F, Fiorito J, Arancio O.

J Alzheimers Dis. 2016;52(1):295-302. doi: 10.3233/JAD-151104.

12.

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.

Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D'Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O.

Sci Rep. 2016 Jan 20;6:19393. doi: 10.1038/srep19393.

13.

Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease.

Fà M, Zhang H, Staniszewski A, Saeed F, Shen LW, Schiefer IT, Siklos MI, Tapadar S, Litosh VA, Libien J, Petukhov PA, Teich AF, Thatcher GR, Arancio O.

J Alzheimers Dis. 2016;49(3):707-21. doi: 10.3233/JAD-150618.

PMID:
26484927
14.

Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.

Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, Teich AF, Arancio O, Bachstetter AD, Webster SJ, Van Eldik LJ, Minasov G, Anderson WF, Pelletier JC, Watterson DM.

ACS Chem Neurosci. 2015 Apr 15;6(4):666-80. doi: 10.1021/acschemneuro.5b00002. Epub 2015 Feb 23.

15.

Synaptic therapy in Alzheimer's disease: a CREB-centric approach.

Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, Fa' M, Arancio O.

Neurotherapeutics. 2015 Jan;12(1):29-41. doi: 10.1007/s13311-014-0327-5. Review.

16.

Resolution of urticarial vasculitis after treatment of neurocysticercosis.

Shaigany S, Dabela E, Teich AF, Husain S, Grossman ME.

J Am Acad Dermatol. 2015 Jan;72(1):e32-3. doi: 10.1016/j.jaad.2014.09.017. No abstract available.

17.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

18.

MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.

Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, Yun J, Samanamud J, Sims JS, Banu M, Dovas A, Teich AF, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Sims PA, Canoll P.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12550-5. doi: 10.1073/pnas.1405839111. Epub 2014 Aug 11.

19.

A reliable way to detect endogenous murine β-amyloid.

Teich AF, Patel M, Arancio O.

PLoS One. 2013;8(2):e55647. doi: 10.1371/journal.pone.0055647. Epub 2013 Feb 1.

20.

Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Teich AF, Arancio O.

Biochem J. 2012 Sep 1;446(2):165-77. doi: 10.1042/BJ20120653. Review.

21.

5-HT₄ receptor stimulation leads to soluble AβPPα production through MMP-9 upregulation.

Hashimoto G, Sakurai M, Teich AF, Saeed F, Aziz F, Arancio O.

J Alzheimers Dis. 2012;32(2):437-45. doi: 10.3233/JAD-2012-111235.

PMID:
22810092
22.

Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.

Qin Z, Luo J, VandeVrede L, Tavassoli E, Fa' M, Teich AF, Arancio O, Thatcher GR.

J Med Chem. 2012 Aug 9;55(15):6784-801. doi: 10.1021/jm300353r. Epub 2012 Jul 24.

23.

'Pontinization' of the medulla: two clinical case studies.

Teich AF, Hedley-Whyte ET, Goldman JE.

Neuropathol Appl Neurobiol. 2011 Oct;37(6):689-93. doi: 10.1111/j.1365-2990.2011.01171.x. No abstract available.

PMID:
21450049
24.

Imaging inflammation in a patient with epilepsy due to focal cortical dysplasia.

Butler T, Ichise M, Teich AF, Gerard E, Osborne J, French J, Devinsky O, Kuzniecky R, Gilliam F, Pervez F, Provenzano F, Goldsmith S, Vallabhajosula S, Stern E, Silbersweig D.

J Neuroimaging. 2013 Jan;23(1):129-31. doi: 10.1111/j.1552-6569.2010.00572.x. Epub 2011 Jan 11.

25.

V1 orientation plasticity is explained by broadly tuned feedforward inputs and intracortical sharpening.

Teich AF, Qian N.

Vis Neurosci. 2010 Mar;27(1-2):57-73. doi: 10.1017/S0952523810000039. Epub 2010 Apr 16.

26.

Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromuscular synapses.

Pang ZP, Melicoff E, Padgett D, Liu Y, Teich AF, Dickey BF, Lin W, Adachi R, Südhof TC.

J Neurosci. 2006 Dec 27;26(52):13493-504.

27.

Comparison among some models of orientation selectivity.

Teich AF, Qian N.

J Neurophysiol. 2006 Jul;96(1):404-19. Epub 2006 Apr 19.

28.

Learning and adaptation in a recurrent model of V1 orientation selectivity.

Teich AF, Qian N.

J Neurophysiol. 2003 Apr;89(4):2086-100. Epub 2002 Dec 18.

Supplemental Content

Loading ...
Support Center